CN101068548B - 用于减少、稳定富含脂质的斑块和/或防止富含脂质的斑块破裂的方法 - Google Patents

用于减少、稳定富含脂质的斑块和/或防止富含脂质的斑块破裂的方法 Download PDF

Info

Publication number
CN101068548B
CN101068548B CN2005800416162A CN200580041616A CN101068548B CN 101068548 B CN101068548 B CN 101068548B CN 2005800416162 A CN2005800416162 A CN 2005800416162A CN 200580041616 A CN200580041616 A CN 200580041616A CN 101068548 B CN101068548 B CN 101068548B
Authority
CN
China
Prior art keywords
pitavastatin
lipid
compound
pharmaceutically acceptable
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800416162A
Other languages
English (en)
Chinese (zh)
Other versions
CN101068548A (zh
Inventor
小林秀之
吉中康展
涉谷公幸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of CN101068548A publication Critical patent/CN101068548A/zh
Application granted granted Critical
Publication of CN101068548B publication Critical patent/CN101068548B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2005800416162A 2004-12-10 2005-12-09 用于减少、稳定富含脂质的斑块和/或防止富含脂质的斑块破裂的方法 Expired - Fee Related CN101068548B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63453204P 2004-12-10 2004-12-10
US60/634,532 2004-12-10
PCT/JP2005/023088 WO2006064889A1 (en) 2004-12-10 2005-12-09 Method for reduction, stabilization and prevention of rupture of lipid rich plaque

Publications (2)

Publication Number Publication Date
CN101068548A CN101068548A (zh) 2007-11-07
CN101068548B true CN101068548B (zh) 2010-12-08

Family

ID=36587943

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800416162A Expired - Fee Related CN101068548B (zh) 2004-12-10 2005-12-09 用于减少、稳定富含脂质的斑块和/或防止富含脂质的斑块破裂的方法

Country Status (11)

Country Link
US (2) US20090275595A1 (enExample)
EP (1) EP1827440A4 (enExample)
JP (1) JP2008522955A (enExample)
KR (1) KR100895031B1 (enExample)
CN (1) CN101068548B (enExample)
AU (1) AU2005314810B2 (enExample)
CA (1) CA2590224C (enExample)
NZ (1) NZ554924A (enExample)
RU (1) RU2351337C1 (enExample)
TW (1) TW200619204A (enExample)
WO (1) WO2006064889A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100438872C (zh) * 2003-08-29 2008-12-03 兴和株式会社 2-[4-[2-(苯并咪唑-2-基-硫代)乙基]哌嗪-1-基]-n-[2,4-二(甲基硫代)-6-甲基-3-吡啶基]乙酰胺的制药用途
US8048083B2 (en) * 2004-11-05 2011-11-01 Dfine, Inc. Bone treatment systems and methods
WO2011081118A1 (ja) * 2009-12-29 2011-07-07 興和株式会社 経口投与用医薬組成物
JPWO2011081117A1 (ja) * 2009-12-29 2013-05-09 興和株式会社 経口投与用固形医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1201389A (zh) * 1995-11-02 1998-12-09 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物
CN1258283A (zh) * 1997-05-26 2000-06-28 兴和株式会社 新的环状二胺化合物及含有它的药物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6969711B2 (en) * 1997-05-26 2005-11-29 Kowa Company, Ltd. Cyclic diamine compounds and medicine containing the same
RU2235483C2 (ru) * 1998-11-25 2004-09-10 Нутри Фарма Аса Композиция, фармацевтический препарат и способ для профилактики и/или лечения и/или ослабления сердечно-сосудистых заболеваний
WO2001022962A1 (en) * 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
IL153633A0 (en) * 2000-07-13 2003-07-06 Takeda Chemical Insustries Ltd Lipid-rich plaque inhibitors
HUP0301728A3 (en) * 2000-09-01 2004-05-28 Sankyo Co Hmg-coa reductase inhibiting pharmaceutical compositions and their use
US20060165605A1 (en) * 2001-12-28 2006-07-27 Ye-Mon Chen Process to regenerate fcc spent catalyst
MY140618A (en) * 2003-02-28 2009-12-31 Kowa Co Method for preparing acid addition salts of polyacidic basic compounds
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1201389A (zh) * 1995-11-02 1998-12-09 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物
CN1258283A (zh) * 1997-05-26 2000-06-28 兴和株式会社 新的环状二胺化合物及含有它的药物

Also Published As

Publication number Publication date
US20090275595A1 (en) 2009-11-05
RU2351337C1 (ru) 2009-04-10
EP1827440A4 (en) 2010-12-08
AU2005314810B2 (en) 2010-08-26
HK1111356A1 (en) 2008-08-08
TW200619204A (en) 2006-06-16
US20110207742A1 (en) 2011-08-25
CA2590224C (en) 2011-12-20
RU2007125976A (ru) 2009-01-20
KR100895031B1 (ko) 2009-04-24
NZ554924A (en) 2010-09-30
CN101068548A (zh) 2007-11-07
KR20070085508A (ko) 2007-08-27
AU2005314810A1 (en) 2006-06-22
EP1827440A1 (en) 2007-09-05
JP2008522955A (ja) 2008-07-03
WO2006064889A1 (en) 2006-06-22
CA2590224A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
US20110015206A1 (en) Method of stabilizing lipid-rich plaque and method of preventing rupture thereof
EP1919466B9 (en) Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative
US20150272944A1 (en) Novel triglyceride reducing agent
US20110207742A1 (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
WO2002030425A1 (en) Preventives and remedies for complications of diabetes
JP2007513991A (ja) メタボリック症候群の処置のためのスタチンの使用
HK1111356B (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
US20130095059A1 (en) Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model
WO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤
CN1252714A (zh) 用于预防再狭窄的制剂
JP2005053890A (ja) アディポネクチン濃度低下及び／又はｃ反応性蛋白濃度上昇及び／又はｉｌ−１８濃度上昇に起因する疾患の予防及び／又は治療剤。
HK1111632B (en) Novel triglyceride reducing agent
WO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤
JP2007051086A (ja) コラーゲンまたはエラスチン代謝異常疾患の予防剤および治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1111356

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1111356

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101208

Termination date: 20121209